OBJECTIVES: To assess cost-effectiveness of indapamide 1.5 mg +amlodipine 5/10 mg single-pill combination (SPC) compared with free combination (FC), in the Polish setting. METHODS: A Markov cohort simulation model was used. Results of meta-analysis by Gupta et al show a difference in patients’ compliance between SPC and FC. Better compliance results in lower systolic blood pressure, which influences risk of cardiovascular events. Hence, compliance is associated with life expectancy and quality of life. Cardiovascular disease risks were based on the Framingham risk equations. Life-time horizon, Polish public payer perspective and patient perspective were applied. Indapamide/amlodipine SPC cost is based on average pharmacy prices reported in April 2014 (18.13PLN and 19.75PLN respectively for 1.5+5mg and 1.5+10mg /30 tabs); 30% patient copayment was assumed. Cost of FC was calculated as an average cost of reimbursed indapamide and amlodipine products in corresponding doses. All costs present 2014 values, and are expressed in Polish zloty (PLN). Costs and effects were discounted with 5% and 3.5% rates. RESULTS: Indapamide/amlodipine SPC compared with FC generates additional life years (LYs) and quality adjusted life years (QALYs), and is highly cost-effective from public payer perspective and dominant from patient perspective. Difference between SPC and FC in LYs and QALYs was: 0.007960 and 0.020809. Difference in total costs from public payer perspective and from patient perspective was 113.14PLN (27.07EUR) and -211.31PLN (-50.56 EUR). ICUR from public payer perspective was 5,437PLN/QALY (1,301EUR/QALY). At prices +199% vs the base-case, SPC remains a cost-effective technology from public payer perspective according to the legally defined CE threshold (111,381PLN/QALY=26,653EUR/QALY). At prices -9.9% vs base-case, SPC is a dominant/cost saving technology vs the FC comparator. CONCLUSIONS: From public payer perspective, indapamide/amlodipine SPC compared with FC is a highly cost-effective treatment option for hypertensive patients in contemporary Polish setting. From patient perspective, SPC is a dominant technology.